Depression, Postpartum
Conditions
Keywords
SAGE-217, Postpartum depression
Brief summary
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Detailed description
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
Interventions
SAGE-217 oral capsules.
SAGE-217 matched-placebo oral capsules.
Sponsors
Study design
Eligibility
Inclusion criteria
* Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP. * Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT). * Participant is ≤12 months postpartum at screening and Day 1.
Exclusion criteria
* Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD. * Participant has active psychosis per investigator assessment. * Participant has a medical history of nonfebrile seizures. * Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder. * Participant has a history of sleep apnea. Note: Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 | Baseline and Day 15 | The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score | Baseline and Day 15 | The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. A participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= extremely ill participants. A lower score indicates a better outcome. A negative change from baseline indicates improvement. MMRM was used for the analysis. |
| Percentage of Participants With HAM-D Response | Days 15 and 45 | The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D response was defined as a ≥50% reduction in HAM-D total score from baseline. |
| Percentage of Participants With HAM-D Remission | Days 15 and 45 | The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D remission was defined as having a HAM-D total score of ≤7. |
| Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response | Day 15 | The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I was only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of very much improved or much improved. |
| Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score | Baseline and Day 15 | The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each 14-items were defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56 where \<17 indicated mild severity, 18 to 24, mild to moderate severity, and 25 to 30, moderate to severe severity. A negative change from baseline in HAM-A total score indicated improvement. |
| Change From Baseline in the 17-item HAM-D Total Score | Baseline, Days 3, 28 and 45 | The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. MMRM was used for the analysis. |
| Change From Baseline in HAM-D Subscale | Baseline and Day 15 | 17-item HAM-D scale is used for severity of depression. HAM-D subscales: Core subscale(depressed mood, feelings of guilt, suicide, work and activities, and retardation/20x100; Anxiety subscale\[anxiety(psychic and somatic), somatic symptoms (gastrointestinal and general), hypochondriasis, and insight loss of weight\]/18x100; Bech-6 subscale(depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general)/22x100; Maier score(depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic)/24x100. Each item was scored in range of 0 to 2 or 0 to 4 (0=none to 2 or 4=severe), higher score=more depression. 4 Subscale scores were calculated as sum of individual rating scores related to each subscale, divided by total possible score within subscale, multiplied by 100. Scores were transformed to scale of 0 to 100, with higher scores=more severe depression. Negative CFB=improvement. MMRM was used for analysis. |
| Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Baseline, Days 3, 8,15, 21, 28 and 45 | The EPDS is a self-rated depressive symptom severity scale specific to the perinatal period which consists of 10 individual items. Each item is rated on a 4-point scale ranging from 0 to 3 points. The EPDS total score is calculated as the sum of the 10 individual item scores, ranging from 0 points to 30 points with a higher score indicating more depression. A negative change indicates improvement. |
| Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Baseline, Days 3, 8,15, 21, 28 and 45 | The PHQ-9 is a self-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants responses to 9 specific questions as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The score were calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression; and 20 to 27 = severe depression. The PHQ-9 total score ranges from 1 to 27 with a higher score indicating more depression. A negative change from baseline indicates reduced depression. MMRM was used for the analysis. |
| Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | Up to Day 45 | An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. |
| Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score | Baseline and Day 15 | The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item is rated on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from baseline in MADRS total score indicated improvement. |
Countries
Spain, United Kingdom, United States
Participant flow
Recruitment details
Participants took part in study at 92 investigational sites in Spain, United Kingdom and United States from 8 June 2020 to 12 April 2022.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days. | 98 |
| SAGE-217 50 mg Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days. | 98 |
| Total | 196 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 1 |
| Overall Study | Lost to Follow-up | 8 | 6 |
| Overall Study | Physician Decision | 0 | 2 |
| Overall Study | Randomized but not Treated | 3 | 1 |
| Overall Study | Reason not Specified | 0 | 1 |
| Overall Study | Withdrawal by Subject | 3 | 4 |
Baseline characteristics
| Characteristic | SAGE-217 50 mg | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 30.0 years STANDARD_DEVIATION 5.9 | 30.5 years STANDARD_DEVIATION 5.93 | 31.0 years STANDARD_DEVIATION 5.95 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 33 Participants | 75 Participants | 42 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 64 Participants | 120 Participants | 56 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 25 Participants | 43 Participants | 18 Participants |
| Race (NIH/OMB) More than one race | 3 Participants | 5 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 6 Participants | 5 Participants |
| Race (NIH/OMB) White | 68 Participants | 137 Participants | 69 Participants |
| Sex: Female, Male Female | 98 Participants | 196 Participants | 98 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 98 | 0 / 98 |
| other Total, other adverse events | 52 / 98 | 64 / 98 |
| serious Total, serious adverse events | 0 / 98 | 2 / 98 |
Outcome results
Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis.
Time frame: Baseline and Day 15
Population: Full Analysis Set(FAS)=randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM for Anxiety(HAM-A), Montgomery Åsberg Depression Rating Scale(MADRS), Clinical Global Impressions-Severity(CGI-S), Edinburgh Postnatal Depression Scale(EPDS) and Patient Health Questionnaire(PHQ-9), or at least 1 post-baseline value of CGI-I. Number analyzed=number of participants with data available for analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 | Baseline | 28.8 score on a scale | Standard Deviation 2.34 |
| Placebo | Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 | Change from Baseline at Day 15 | -11.4 score on a scale | Standard Deviation 8.5 |
| SAGE-217 50 mg | Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 | Baseline | 28.6 score on a scale | Standard Deviation 2.49 |
| SAGE-217 50 mg | Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 | Change from Baseline at Day 15 | -15.6 score on a scale | Standard Deviation 7.62 |
Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score
The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. A participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= extremely ill participants. A lower score indicates a better outcome. A negative change from baseline indicates improvement. MMRM was used for the analysis.
Time frame: Baseline and Day 15
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score | Baseline | 4.9 score on a scale | Standard Deviation 0.58 |
| Placebo | Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score | Change from Baseline at Day 15 | -1.6 score on a scale | Standard Deviation 1.38 |
| SAGE-217 50 mg | Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score | Baseline | 5.0 score on a scale | Standard Deviation 0.66 |
| SAGE-217 50 mg | Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score | Change from Baseline at Day 15 | -2.2 score on a scale | Standard Deviation 1.51 |
Change From Baseline in HAM-D Subscale
17-item HAM-D scale is used for severity of depression. HAM-D subscales: Core subscale(depressed mood, feelings of guilt, suicide, work and activities, and retardation/20x100; Anxiety subscale\[anxiety(psychic and somatic), somatic symptoms (gastrointestinal and general), hypochondriasis, and insight loss of weight\]/18x100; Bech-6 subscale(depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general)/22x100; Maier score(depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic)/24x100. Each item was scored in range of 0 to 2 or 0 to 4 (0=none to 2 or 4=severe), higher score=more depression. 4 Subscale scores were calculated as sum of individual rating scores related to each subscale, divided by total possible score within subscale, multiplied by 100. Scores were transformed to scale of 0 to 100, with higher scores=more severe depression. Negative CFB=improvement. MMRM was used for analysis.
Time frame: Baseline and Day 15
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in HAM-D Subscale | Core Subscale Baseline | 47.6 score on a scale | Standard Deviation 6.96 |
| Placebo | Change From Baseline in HAM-D Subscale | Change from Baseline in Core Subscale at Day 15 | -20.4 score on a scale | Standard Deviation 18.49 |
| Placebo | Change From Baseline in HAM-D Subscale | Anxiety Subscale Baseline | 52.6 score on a scale | Standard Deviation 9.23 |
| Placebo | Change From Baseline in HAM-D Subscale | Change from Baseline in Anxiety Subscale at Day 15 | -20.4 score on a scale | Standard Deviation 17.28 |
| Placebo | Change From Baseline in HAM-D Subscale | Bech-6-Subscale Baseline | 62.9 score on a scale | Standard Deviation 6.14 |
| Placebo | Change From Baseline in HAM-D Subscale | Change from Baseline in Bech-6 Subscale at Day 15 | -24.6 score on a scale | Standard Deviation 21.37 |
| Placebo | Change From Baseline in HAM-D Subscale | Meier Subscale Baseline | 56.3 score on a scale | Standard Deviation 5.94 |
| Placebo | Change From Baseline in HAM-D Subscale | Change from Baseline in Meier Subscale at Day 15 | -22.5 score on a scale | Standard Deviation 18.99 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Change from Baseline in Meier Subscale at Day 15 | -30.7 score on a scale | Standard Deviation 17.23 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Core Subscale Baseline | 49.2 score on a scale | Standard Deviation 6.79 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Bech-6-Subscale Baseline | 63.7 score on a scale | Standard Deviation 5.64 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Change from Baseline in Core Subscale at Day 15 | -27.7 score on a scale | Standard Deviation 16.36 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Meier Subscale Baseline | 56.9 score on a scale | Standard Deviation 6.11 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Anxiety Subscale Baseline | 51.2 score on a scale | Standard Deviation 8.79 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Change from Baseline in Bech-6 Subscale at Day 15 | -34.3 score on a scale | Standard Deviation 19.61 |
| SAGE-217 50 mg | Change From Baseline in HAM-D Subscale | Change from Baseline in Anxiety Subscale at Day 15 | -26.0 score on a scale | Standard Deviation 15.66 |
Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each 14-items were defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56 where \<17 indicated mild severity, 18 to 24, mild to moderate severity, and 25 to 30, moderate to severe severity. A negative change from baseline in HAM-A total score indicated improvement.
Time frame: Baseline and Day 15
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number of participants analyzed is the number of participants with data available for analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score | Baseline | 24.7 score on a scale | Standard Deviation 5.96 |
| Placebo | Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score | Change from Baseline at Day 15 | -10.4 score on a scale | Standard Deviation 7.15 |
| SAGE-217 50 mg | Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score | Baseline | 24.4 score on a scale | Standard Deviation 6.01 |
| SAGE-217 50 mg | Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score | Change from Baseline at Day 15 | -13.0 score on a scale | Standard Deviation 8.19 |
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score
The PHQ-9 is a self-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants responses to 9 specific questions as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The score were calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression; and 20 to 27 = severe depression. The PHQ-9 total score ranges from 1 to 27 with a higher score indicating more depression. A negative change from baseline indicates reduced depression. MMRM was used for the analysis.
Time frame: Baseline, Days 3, 8,15, 21, 28 and 45
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed are the number of participants with data available for analysis.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change form Baseline at Day 3 | -2.3 score on a scale | Standard Error 0.462 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 8 | -5.9 score on a scale | Standard Error 0.617 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 15 | -8.6 score on a scale | Standard Error 0.652 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 21 | -9.0 score on a scale | Standard Error 0.655 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 28 | -9.2 score on a scale | Standard Error 0.692 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 45 | -9.8 score on a scale | Standard Error 0.728 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 28 | -10.5 score on a scale | Standard Error 0.703 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change form Baseline at Day 3 | -2.0 score on a scale | Standard Error 0.456 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 21 | -10.6 score on a scale | Standard Error 0.651 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 8 | -7.7 score on a scale | Standard Error 0.62 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 45 | -11.7 score on a scale | Standard Error 0.731 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score | Change from Baseline at Day 15 | -10.5 score on a scale | Standard Error 0.651 |
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score
The EPDS is a self-rated depressive symptom severity scale specific to the perinatal period which consists of 10 individual items. Each item is rated on a 4-point scale ranging from 0 to 3 points. The EPDS total score is calculated as the sum of the 10 individual item scores, ranging from 0 points to 30 points with a higher score indicating more depression. A negative change indicates improvement.
Time frame: Baseline, Days 3, 8,15, 21, 28 and 45
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 15 | -8.0 score on a scale | Standard Deviation 6.41 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 21 | -8.7 score on a scale | Standard Deviation 6.65 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Baseline | 20.0 score on a scale | Standard Deviation 4.15 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 28 | -9.4 score on a scale | Standard Deviation 6.48 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 8 | -6.0 score on a scale | Standard Deviation 6.2 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 45 | -9.7 score on a scale | Standard Deviation 7.4 |
| Placebo | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 3 | -2.2 score on a scale | Standard Deviation 4.5 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 45 | -12.3 score on a scale | Standard Deviation 7.87 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Baseline | 21.1 score on a scale | Standard Deviation 3.68 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 3 | -4.2 score on a scale | Standard Deviation 5.34 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 8 | -8.9 score on a scale | Standard Deviation 7.01 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 21 | -10.9 score on a scale | Standard Deviation 6.72 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 28 | -11.6 score on a scale | Standard Deviation 7.83 |
| SAGE-217 50 mg | Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score | Change from Baseline at Day 15 | -10.8 score on a scale | Standard Deviation 7.18 |
Change From Baseline in the 17-item HAM-D Total Score
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. MMRM was used for the analysis.
Time frame: Baseline, Days 3, 28 and 45
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the 17-item HAM-D Total Score | Baseline | 28.8 score on a scale | Standard Deviation 2.34 |
| Placebo | Change From Baseline in the 17-item HAM-D Total Score | Change from Baseline at Day 3 | -6.3 score on a scale | Standard Deviation 6.78 |
| Placebo | Change From Baseline in the 17-item HAM-D Total Score | Change from Baseline at Day 28 | -13.5 score on a scale | Standard Deviation 8.77 |
| Placebo | Change From Baseline in the 17-item HAM-D Total Score | Change from Baseline at Day 45 | -14.8 score on a scale | Standard Deviation 9.09 |
| SAGE-217 50 mg | Change From Baseline in the 17-item HAM-D Total Score | Change from Baseline at Day 45 | -17.7 score on a scale | Standard Deviation 8.4 |
| SAGE-217 50 mg | Change From Baseline in the 17-item HAM-D Total Score | Baseline | 28.6 score on a scale | Standard Deviation 2.49 |
| SAGE-217 50 mg | Change From Baseline in the 17-item HAM-D Total Score | Change from Baseline at Day 28 | -16.3 score on a scale | Standard Deviation 8.34 |
| SAGE-217 50 mg | Change From Baseline in the 17-item HAM-D Total Score | Change from Baseline at Day 3 | -9.5 score on a scale | Standard Deviation 7.4 |
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item is rated on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from baseline in MADRS total score indicated improvement.
Time frame: Baseline and Day 15
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Overall number analyzed are the number of participants available for analysis. Number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score | Baseline | 35.0 score on a scale | Standard Deviation 4.81 |
| Placebo | Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score | Change from Baseline at Day 15 | -14.1 score on a scale | Standard Deviation 11.78 |
| SAGE-217 50 mg | Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score | Baseline | 35.5 score on a scale | Standard Deviation 5.37 |
| SAGE-217 50 mg | Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score | Change from Baseline at Day 15 | -19.9 score on a scale | Standard Deviation 12 |
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.
Time frame: Up to Day 45
Population: Safety Set included all participants who were administered IP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | 53.1 percentage of participants |
| SAGE-217 50 mg | Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | 66.3 percentage of participants |
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I was only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of very much improved or much improved.
Time frame: Day 15
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Overall number analyzed is the number of participants available for analyses. Number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response | 46.7 percentage of participants |
| SAGE-217 50 mg | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response | 66.7 percentage of participants |
Percentage of Participants With HAM-D Remission
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D remission was defined as having a HAM-D total score of ≤7.
Time frame: Days 15 and 45
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants with data available for analyses. Percentages are rounded off to the nearest whole number.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants With HAM-D Remission | Day 15 | 16.7 percentage of participants |
| Placebo | Percentage of Participants With HAM-D Remission | Day 45 | 29.4 percentage of participants |
| SAGE-217 50 mg | Percentage of Participants With HAM-D Remission | Day 15 | 26.9 percentage of participants |
| SAGE-217 50 mg | Percentage of Participants With HAM-D Remission | Day 45 | 44.0 percentage of participants |
Percentage of Participants With HAM-D Response
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D response was defined as a ≥50% reduction in HAM-D total score from baseline.
Time frame: Days 15 and 45
Population: FAS included all randomized participants who received any amount of IP and had valid baseline and at least one valid post-baseline total score in at least one of HAM-D, HAM-A, MADRS, CGI-S, EPDS and PHQ-9, or at least 1 post-baseline value of CGI-I. Number analyzed is the number of participants available for analyses. Percentages are rounded off to the nearest whole number.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants With HAM-D Response | Day 15 | 38.9 percentage of participants |
| Placebo | Percentage of Participants With HAM-D Response | Day 45 | 54.1 percentage of participants |
| SAGE-217 50 mg | Percentage of Participants With HAM-D Response | Day 15 | 57.0 percentage of participants |
| SAGE-217 50 mg | Percentage of Participants With HAM-D Response | Day 45 | 61.9 percentage of participants |